RU2016104221A - Имидазолкарбоксамиды и их применение в качестве ингибиторов гидролазы амидов жирных кислот - Google Patents
Имидазолкарбоксамиды и их применение в качестве ингибиторов гидролазы амидов жирных кислот Download PDFInfo
- Publication number
- RU2016104221A RU2016104221A RU2016104221A RU2016104221A RU2016104221A RU 2016104221 A RU2016104221 A RU 2016104221A RU 2016104221 A RU2016104221 A RU 2016104221A RU 2016104221 A RU2016104221 A RU 2016104221A RU 2016104221 A RU2016104221 A RU 2016104221A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- composition according
- compound
- disease
- pharmaceutical composition
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 239000004093 hydrolase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims 2
- 229950007031 palmidrol Drugs 0.000 claims 2
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical class [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 159000000021 acetate salts Chemical class 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960003920 ***e Drugs 0.000 claims 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 239000002621 endocannabinoid Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 claims 1
- 230000003893 regulation of appetite Effects 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
Claims (17)
1. Соединение, имеющее структуру, выбранную из следующих:
или его фармацевтически приемлемая соль.
2. Соединение по п. 1, где фармацевтически приемлемая соль представляет собой гидрохлоридную соль, ацетатную соль, трифторацетатную соль, метансульфонатную соль, 2-гидроксипропан-1,2,2-трикарбоксилатную соль, (2R,3R)-2,3-дигидроксисукцинатную соль, фосфатную соль, сульфатную соль, бензоатную соль, 2-гидроксибензоатную соль, S-(+)-манделатную соль, S-(-)-малатную соль, S-(-)пироглутаматную соль, пируватную соль, пара-толуолсульфонатную соль, 1-R-(-)-камфорсульфонатную соль, фумаратную соль, малеатную соль или оксалатную соль.
3. Фармацевтическая композиция, содержащая соединение по п. 1 вместе с одним или более фармацевтически приемлемых эксципиентов.
4. Фармацевтическая композиция по п. 3, дополнительно содержащая один или более дополнительных активных фармацевтических ингредиентов.
5. Фармацевтическая композиция по п. 4, где один или более дополнительных активных фармацевтических ингредиентов выбраны из анандамида, олеоилэтаноламида и пальмитоилэтаноламида.
6. Фармацевтическая композиция по любому из пп. 3-5, где композиция предназначена для перорального введения.
7. Фармацевтическая композиция по любому из пп. 3-5, где композиция находится в форме стерильного инъекционного препарата.
8. Применение соединения по п. 1 или 2, или композиции по любому из пп. 3-7 в терапии.
9. Применение соединения по п. 1 или 2 в лечении или профилактике состояния, развитие или симптомы которого связаны с субстратом фермента FAAH (от. англ. fatty acid amide hydrolase - гидролаза амидов жирных кислот).
10. Применение по п. 9, где состояние представляет собой расстройство, связанное с эндоканнабиноидной системой.
11. Применение по п. 10, где расстройство выбирают из регуляции аппетита, ожирения, нарушения обмена веществ, кахексии, анорексии, боли, воспаления, нейротоксичности, нейротравмы, инсульта, рассеянного склероза, травмы спинного мозга, болезни Паркинсона, леводопа-индуцированной дискинезии, болезни Хантингтона, синдрома Жиля де ла Туретта, поздней дискинезии, дистонии, амиотрофического бокового склероза, болезни Альцгеймера, эпилепсии, шизофрении, тревоги, депрессии, бессонницы, тошноты, рвоты, алкогольных расстройств, привыкания к наркотическим средствам, таким как опиаты, никотин, кокаин, алкоголь и психостимуляторы, гипертонии, циркуляторного шока, реперфузионного повреждения миокарда, атеросклероза, астмы, глазной гипертензии, глаукомы, ретинопатии, рака, воспалительного заболевания кишечника, острого и хронического заболевания печени, такого как гепатит и цирроз печени, артрита и остеопороза.
12. Применение по любому из пп. 9-11, где соединение предназначено для введения одновременно или со смещением во времени с одним или более дополнительных активных фармацевтических ингредиентов.
13. Применение по п. 12, где один или более дополнительных активных фармацевтических ингредиентов выбирают из анандамида, олеоилэтаноламида и пальмитоилэтаноламида.
14. Способ лечения или профилактики состояния, развитие или симптомы которого связаны с субстратом фермента FAAH, включающий введение пациенту,
нуждающемуся в таком лечении или профилактике, терапевтически эффективного количества соединения по п. 1 или композиции по п. 3.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201313202A GB201313202D0 (en) | 2013-07-24 | 2013-07-24 | Urea Compound And Its Use As An Enzyme Inhibitor |
| GB1313203.0 | 2013-07-24 | ||
| GB201313203A GB201313203D0 (en) | 2013-07-24 | 2013-07-24 | Urea compound and its use as an enzyme inhibitor |
| GB1313204.8 | 2013-07-24 | ||
| GB1313202.2 | 2013-07-24 | ||
| GB201313204A GB201313204D0 (en) | 2013-07-24 | 2013-07-24 | Urea compound and its use as an enzyme inhibitor |
| PCT/PT2014/000049 WO2015012708A1 (en) | 2013-07-24 | 2014-07-24 | Imidazolecarboxamides and their use as faah inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016104221A true RU2016104221A (ru) | 2017-08-29 |
| RU2671404C2 RU2671404C2 (ru) | 2018-10-31 |
Family
ID=51358056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016104221A RU2671404C2 (ru) | 2013-07-24 | 2014-07-24 | Имидазолкарбоксамиды и их применение в качестве ингибиторов гидролазы амидов жирных кислот |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10501447B2 (ru) |
| EP (1) | EP3024825B1 (ru) |
| JP (1) | JP6449277B2 (ru) |
| KR (1) | KR20160034359A (ru) |
| CN (1) | CN105793247B (ru) |
| AU (1) | AU2014293731B2 (ru) |
| CA (1) | CA2918993C (ru) |
| CY (1) | CY1119482T1 (ru) |
| DK (1) | DK3024825T3 (ru) |
| ES (1) | ES2640800T3 (ru) |
| HR (1) | HRP20171378T1 (ru) |
| HU (1) | HUE033615T2 (ru) |
| LT (1) | LT3024825T (ru) |
| MX (1) | MX362315B (ru) |
| PL (1) | PL3024825T3 (ru) |
| PT (1) | PT3024825T (ru) |
| RS (1) | RS56297B1 (ru) |
| RU (1) | RU2671404C2 (ru) |
| SI (1) | SI3024825T1 (ru) |
| WO (1) | WO2015012708A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| SG10201807034XA (en) | 2017-09-05 | 2019-04-29 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| EP0014810A3 (en) | 1979-01-18 | 1980-11-26 | Fbc Limited | Pesticidal pyrazoles, their production, compositions and uses, as well as intermediates and their preparation |
| JPH01203366A (ja) | 1988-02-10 | 1989-08-16 | Mitsui Petrochem Ind Ltd | Ｎ−置換イミダゾール誘導体 |
| WO1994010158A1 (en) | 1992-10-28 | 1994-05-11 | Toyama Chemical Co., Ltd. | Novel 1,2-benzisoxazole derivative or salt thereof, and brain protective agent comprising the same |
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| HUE033441T2 (en) * | 2004-12-30 | 2017-11-28 | Janssen Pharmaceutica Nv | 4- (Benzyl) piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid hydrolase (phaha) for the treatment of anxiety, pain and other diseases |
| FI20075264A0 (fi) | 2007-04-18 | 2007-04-18 | Kuopion Yliopisto | Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina |
| US8324241B2 (en) | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| CN103140478A (zh) | 2010-07-29 | 2013-06-05 | 比亚尔-珀特拉和Ca股份公司 | 取代的脲化合物的合成方法 |
| FR2965262A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| WO2014017936A2 (en) | 2012-07-24 | 2014-01-30 | Bial- Portela & Ca, S.A. | Urea compounds and their use as enzyme inhibitors |
-
2014
- 2014-07-24 CA CA2918993A patent/CA2918993C/en not_active Expired - Fee Related
- 2014-07-24 LT LTEP14752676.8T patent/LT3024825T/lt unknown
- 2014-07-24 JP JP2016529739A patent/JP6449277B2/ja not_active Expired - Fee Related
- 2014-07-24 RU RU2016104221A patent/RU2671404C2/ru active
- 2014-07-24 SI SI201430380T patent/SI3024825T1/sl unknown
- 2014-07-24 PT PT147526768T patent/PT3024825T/pt unknown
- 2014-07-24 RS RS20170905A patent/RS56297B1/sr unknown
- 2014-07-24 HU HUE14752676A patent/HUE033615T2/hu unknown
- 2014-07-24 US US14/906,822 patent/US10501447B2/en not_active Expired - Fee Related
- 2014-07-24 ES ES14752676.8T patent/ES2640800T3/es active Active
- 2014-07-24 DK DK14752676.8T patent/DK3024825T3/en active
- 2014-07-24 WO PCT/PT2014/000049 patent/WO2015012708A1/en active Application Filing
- 2014-07-24 AU AU2014293731A patent/AU2014293731B2/en not_active Ceased
- 2014-07-24 MX MX2016000797A patent/MX362315B/es active IP Right Grant
- 2014-07-24 KR KR1020167004236A patent/KR20160034359A/ko active IP Right Grant
- 2014-07-24 PL PL14752676T patent/PL3024825T3/pl unknown
- 2014-07-24 CN CN201480041611.9A patent/CN105793247B/zh not_active Expired - Fee Related
- 2014-07-24 EP EP14752676.8A patent/EP3024825B1/en active Active
-
2017
- 2017-09-14 HR HRP20171378TT patent/HRP20171378T1/hr unknown
- 2017-09-20 CY CY20171100984T patent/CY1119482T1/el unknown
-
2019
- 2019-12-06 US US16/705,277 patent/US20200255412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3024825T3 (en) | 2017-10-02 |
| US20160176854A1 (en) | 2016-06-23 |
| HRP20171378T1 (hr) | 2017-12-15 |
| WO2015012708A1 (en) | 2015-01-29 |
| JP2016525543A (ja) | 2016-08-25 |
| RS56297B1 (sr) | 2017-12-29 |
| SI3024825T1 (sl) | 2017-11-30 |
| RU2671404C2 (ru) | 2018-10-31 |
| AU2014293731B2 (en) | 2018-03-08 |
| US10501447B2 (en) | 2019-12-10 |
| HUE033615T2 (hu) | 2017-12-28 |
| PL3024825T3 (pl) | 2017-12-29 |
| CN105793247B (zh) | 2018-03-16 |
| KR20160034359A (ko) | 2016-03-29 |
| ES2640800T3 (es) | 2017-11-06 |
| CA2918993C (en) | 2021-08-24 |
| EP3024825B1 (en) | 2017-06-21 |
| PT3024825T (pt) | 2017-09-28 |
| AU2014293731A1 (en) | 2016-02-11 |
| CA2918993A1 (en) | 2015-01-29 |
| CN105793247A (zh) | 2016-07-20 |
| MX362315B (es) | 2019-01-11 |
| EP3024825A1 (en) | 2016-06-01 |
| JP6449277B2 (ja) | 2019-01-09 |
| LT3024825T (lt) | 2017-12-11 |
| MX2016000797A (es) | 2016-09-08 |
| CY1119482T1 (el) | 2018-03-07 |
| US20200255412A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596585A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP5721631B2 (ja) | 酸性セラミダーゼのリソソーム親和性阻害剤 | |
| JP2013545730A5 (ru) | ||
| RU2015104097A (ru) | Соединения мочевины и их применение в качестве ингибиторов ферментов | |
| JP2012097105A5 (ru) | ||
| JP2017119710A (ja) | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 | |
| EP3170494A3 (en) | Tapentadol compositions | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| RU2009145541A (ru) | Терапевтические соединения | |
| RU2008146816A (ru) | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол | |
| HRP20191265T1 (hr) | Supstituirani 2-tiokso-imidazolidin-4-oni i njihovi spiro analozi, aktivni anti-kancerogeni sastojak, farmaceutska kompozicija, medicinski preparat, metoda za liječenje raka prostate | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| RU2013153140A (ru) | Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат | |
| EA201301266A8 (ru) | Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции | |
| RU2016104221A (ru) | Имидазолкарбоксамиды и их применение в качестве ингибиторов гидролазы амидов жирных кислот | |
| JP2018515463A5 (ru) | ||
| CA2870240A1 (en) | Analgesic | |
| JP2012510985A5 (ru) | ||
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2014518552A5 (ru) | ||
| JP2016525543A5 (ru) | ||
| RU2017137008A (ru) | Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени | |
| CN104352488B (zh) | 一类取代杂环衍生物在制备治疗疼痛药物中的应用 | |
| JP2015529196A5 (ru) |